Freya Biosciences

Executive Summary

Freya Biosciences is a clinical-stage Danish biotechnology company pioneering microbial immunotherapies for women's reproductive health. Founded in 2020 and headquartered in Copenhagen, the company focuses on alleviating chronic inflammation underlying a range of gynecological diseases. By targeting the microbiome-immune axis, Freya aims to develop first-in-class treatments for conditions such as endometriosis, recurrent pregnancy loss, and bacterial vaginosis. The company is currently in Phase 1 clinical development, with its lead candidate progressing through early human trials. Despite being at an early stage, Freya's innovative approach addresses a significant unmet need in women's health, a field that has historically received limited R&D investment. The company's unique platform and focus on microbial immunotherapy position it well for potential growth, though clinical validation and funding are key near-term milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead candidate65% success
• TBDStrategic partnership for co-development or licensing50% success
• H2 2026Series A funding round to advance pipeline75% success